Breaking News Instant updates and real-time market news.

CLSD

Clearside Biomedical

$1.14

-0.01 (-0.87%)

08:46
07/31/19
07/31
08:46
07/31/19
08:46

Clearside Biomedical announces multiple presentations at ASRS Annual Meeting

Clearside Biomedical announced that multiple oral presentations were delivered on Clearside's pipeline and proprietary SCS Microinjector targeting the suprachoroidal space. Presentations: Title: Suprachoroidal administration of DNA nanoparticles transfect chorioretinal cells in primates and rabbits: Dr. Kay recorded a video presentation describing the preclinical studies for the use of gene therapy via suprachoroidal injection. The presentation is available as a Paper-On-Demand. In the studies, a luciferase assay was used to study gene expression in the animal models via suprachoroidal administration of DNA nanoparticles. Luciferase activity was observed in the retina and retinal pigment epithelial and choroid of all eyes that received suprachoroidal injection of DNPs. In rabbits, suprachoroidal injection of luciferase DNPs produced activity comparable to that seen from subretinal injections of luciferase DNPs. SCS injections of DNPs were generally well-tolerated across both rabbits and non-human primates, and no significant abnormalities were observed on ophthalmic exams. SCS injections of DNPs may offer the potential for a safe and efficient delivery method, and may address an unmet need in ocular gene delivery. Title: Clinical Experience with the SCS Microinjector for Suprachoroidal Injections by Ophthalmologists: Dr. Shah's presentation described the clinical experience using the SCS Microinjector for suprachoroidal injection of XIPERE. His methods included a physician survey of injection experience, and a post-hoc analysis of two Clearside clinical trials for non-infectious uveitis. Injection survey results revealed little difficulty in following the steps in the procedure and generally no challenges compared to other types of injections. In the post-hoc analysis, the majority of injections were completed with the 900microm needle, and 83% of injections used the same needle length for a patient's two injections. In summary, by utilizing the proper techniques, SCS injections can be easily conducted in a physician's office as a potentially useful targeted delivery of drug to posterior segment pathologies. Title: Suprachoroidal CLS-TA Improves Patient Outcomes in Uveitis of All Anatomic Subtypes: Results of the Phase 3 PEACHTREE Study: In the trial, the distribution of each uveitis anatomic subtype was similar in both the treatment arm and the control arm. Subgroup analyses were performed to evaluate outcomes based on anatomic subtype of uveitis. In the CLS-TA treatment arm, patients all had statistically significant visual acuity gains compared to the sham arm: anterior - 14.4 letters, intermediate - 13.4 letters, posterior - 15.6 letters, panuveitis -12.0 letters. In the CLS-TA treatment arm, patients also all had statistically significant reductions in macular thickness compared to the sham arm at week 24: anterior - 106 microns at week 24, intermediate - 155 microns, posterior- 154 microns, panuveitis - 164 microns. Title: Suprachoroidally Injected CLS-TA in Uveitis Maintains Efficacy Outcomes Through 48 Weeks: Results of the MAGNOLIA Phase 3 Extension Study: In the trial, 50% of patients did not receive additional medication through week 48, which corresponded to 36 weeks after their second of two quarterly, protocol-mandated injections of XIPERE. Suprachoroidally injected XIPERE significantly improved vision and macular edema in MAGNOLIA. There were no serious adverse events related to study medication, and elevations in intraocular pressure were low in number and consistent with those seen in the PEACHTREE trial. Title: Suprachoroidal CLS-TA Plus Aflibercept Compared with Aflibercept Monotherapy for Diabetic Macular Edema: Results of a Phase 2 Trial: The trial demonstrated similar best corrected visual acuity improvements with combination aflibercept and CLS-TA treatment compared to aflibercept monotherapy. Central subfield thickness improvement was significantly greater with combination treatment vs aflibercept monotherapy. Other anatomic outcomes such as diabetic retinopathy severity score and changes in disorganization of the retinal inner layers were similar in both arms. Meaningfully, fewer treatment visits were needed in the combination arm compared to aflibercept monotherapy: 4.7 versus 2.8 mean treatment visits, suggesting the potential to address treatment burden. There were no SAEs assessed as related to study drug or study procedure in either arm.

  • 19

    Oct

CLSD Clearside Biomedical
$1.14

-0.01 (-0.87%)

11/05/18
JPMS
11/05/18
DOWNGRADE
Target $8
JPMS
Underweight
JPMorgan double downgrades Clearside to Underweight on study failure
JPMorgan analyst Anupam Rama double downgraded Clearside Biomedical to Underweight from Overweight and lowered his price target for the shares to $8 from $16. The stock in early trading is down 56%, or $3.12, to $2.44. The analyst also removed Clearside from his firm's Analyst Focus List. The company this morning announced that the Phase 3 Sapphire results for Xipere plus Eylea in retinal vein occlusion did not meet the primary endpoint of third-line gainers versus Eylea alone, Rama tells investors in a research note. The results are "clearly disappointing," says Rama. The analyst sees no material value creation catalysts on the horizon and believes the overall negative sentiment on shares is unlikely to change until the company is closer to approval/commercialization.
11/05/18
COWN
11/05/18
DOWNGRADE
COWN
Market Perform
Clearside Biomedical downgraded earlier to Market Perform at Cowen
11/05/18
STFL
11/05/18
DOWNGRADE
Target $4
STFL
Hold
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy earlier downgraded Clearside Biomedical to Hold from Buy following the failure of the SAPPHIRE trial in RVO and subsequent discontinuation of the program. Clearside's value now depends primarily on the success of Xipere for the treatment of macular edema associated with non-infectious uveitis, said Samimy, who lowered her price target on the stock to $4 from $20. The SAPPHIRE failure also has implications for the future clinical design for DME, since "designing it as a superiority trial appears off the table now," Samimy believes.
11/06/18
NEED
11/06/18
NO CHANGE
Target $4
NEED
Buy
Clearside Biomedical price target lowered to $4 from $22 at Needham
Needham analyst Serge Belanger lowered his price target on Clearside Biomedical to $4 after its announcement yesterday that the Sapphire Phase 3 study evaluating Xipere in RVO patients did not meet its primary endpoint. The analyst also keeps his Buy rating, stating that while Clearside Biomedical is discontinuing the clinical development of its RVO program, it will remain focused on the Xipere opportunity in uveitis. Belanger adds that the valuation on the shares is now below cash levels and fails to capture the uveitis opportunity with potential peak sales of as high as $150M.

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$18.96

0.01 (0.05%)

15:04
08/22/19
08/22
15:04
08/22/19
15:04
Options
HP Inc. options imply 9.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

KKR

KKR

$25.74

0.04 (0.16%)

15:00
08/22/19
08/22
15:00
08/22/19
15:00
Periodicals
Breaking Periodicals news story on KKR »

KKR looking into sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$147.63

0.23 (0.16%)

14:49
08/22/19
08/22
14:49
08/22/19
14:49
Options
Salesforce options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

MYGN

Myriad Genetics

$23.88

-1.24 (-4.94%)

14:44
08/22/19
08/22
14:44
08/22/19
14:44
Recommendations
Myriad Genetics analyst commentary at Piper Jaffray »

LCD's incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 13

    Nov

PINC

Premier

$37.88

0.1 (0.26%)

14:36
08/22/19
08/22
14:36
08/22/19
14:36
Recommendations
Premier analyst commentary at Piper Jaffray »

Piper says Premier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

CAH

Cardinal Health

$43.87

0.31 (0.71%)

14:35
08/22/19
08/22
14:35
08/22/19
14:35
Options
Cardinal Health put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MO

Altria Group

$46.24

-0.01 (-0.02%)

14:30
08/22/19
08/22
14:30
08/22/19
14:30
Hot Stocks
Altria Group raises quarterly dividend to 84c per share from 80c »

Altria Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$204.11

0.27 (0.13%)

, ALXN

Alexion

$125.28

10.41 (9.06%)

14:29
08/22/19
08/22
14:29
08/22/19
14:29
On The Fly
Analyst says rumored Amgen bid for Alexion 'could make a ton of sense' »

After Spanish publication…

AMGN

Amgen

$204.11

0.27 (0.13%)

ALXN

Alexion

$125.28

10.41 (9.06%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 02

    Sep

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

  • 04

    Nov

FL

Foot Locker

$41.82

2.06 (5.18%)

, HIBB

Hibbett Sports

$17.04

0.88 (5.45%)

14:29
08/22/19
08/22
14:29
08/22/19
14:29
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$41.82

2.06 (5.18%)

HIBB

Hibbett Sports

$17.04

0.88 (5.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

CRM

Salesforce

$147.66

0.26 (0.18%)

, INTU

Intuit

$276.18

-0.16 (-0.06%)

14:28
08/22/19
08/22
14:28
08/22/19
14:28
Earnings
Notable companies reporting after market close »

Notable companies…

CRM

Salesforce

$147.66

0.26 (0.18%)

INTU

Intuit

$276.18

-0.16 (-0.06%)

VMW

VMware

$147.20

-0.84 (-0.57%)

ROST

Ross Stores

$107.05

1.37 (1.30%)

HPQ

HP Inc.

$18.95

(0.00%)

GPS

Gap

$17.58

0.62 (3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 10

    Sep

  • 25

    Sep

  • 10

    Oct

  • 27

    Oct

  • 12

    Dec

  • 16

    Dec

SPLK

Splunk

$117.83

-10.68 (-8.31%)

14:24
08/22/19
08/22
14:24
08/22/19
14:24
Recommendations
Splunk analyst commentary at BMO Capital »

BMO Capital remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/22/19
08/22
14:17
08/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/22/19
08/22
14:16
08/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$8.41

-0.28 (-3.22%)

14:15
08/22/19
08/22
14:15
08/22/19
14:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 08

    Oct

  • 09

    Oct

14:15
08/22/19
08/22
14:15
08/22/19
14:15
General news
Breaking General news story  »

Minneapolis Federal…

NWS

News Corp

$14.48

0.02 (0.14%)

, NWSA

News Corp.

$14.17

0.07 (0.50%)

14:12
08/22/19
08/22
14:12
08/22/19
14:12
Periodicals
News Corp prepares news app to address concerns with Google, Facebook, WSJ says »

News Corp (NWSA) is…

NWS

News Corp

$14.48

0.02 (0.14%)

NWSA

News Corp.

$14.17

0.07 (0.50%)

GOOG

Alphabet

$1,191.47

0.68 (0.06%)

GOOGL

Alphabet Class A

$1,192.10

1.84 (0.15%)

FB

Facebook

$181.72

-1.84 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 23

    Sep

  • 24

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,815.98

-7.21 (-0.40%)

14:00
08/22/19
08/22
14:00
08/22/19
14:00
Periodicals
Amazon acquires 49% interest in India's Future Coupons, TechCrunch reports »

Amazon has acquired a 49%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BTHE

Boston Therapeutics

$0.00

(0.00%)

13:56
08/22/19
08/22
13:56
08/22/19
13:56
Hot Stocks
Boston Therapeutics BTI320 Phase 2 study achieves full enrollment »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$212.87

0.18 (0.08%)

, BABA

Alibaba

$171.93

-3.26 (-1.86%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Periodicals
EU targets Apple, Google, others with EUR100B wealth fund plan, Politico says »

EU officials want to set…

AAPL

Apple

$212.87

0.18 (0.08%)

BABA

Alibaba

$171.93

-3.26 (-1.86%)

GOOG

Alphabet

$1,191.36

0.57 (0.05%)

GOOGL

Alphabet Class A

$1,192.66

2.4 (0.20%)

AMZN

Amazon.com

$1,815.25

-7.94 (-0.44%)

FB

Facebook

$182.08

-1.48 (-0.81%)

MSFT

Microsoft

$137.45

-1.32 (-0.95%)

BIDU

Baidu

$105.36

-2.55 (-2.36%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 04

    Sep

  • 04

    Sep

  • 06

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

SEDG

SolarEdge

$80.94

-6.93 (-7.89%)

13:55
08/22/19
08/22
13:55
08/22/19
13:55
Options
SolarEdge put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

13:44
08/22/19
08/22
13:44
08/22/19
13:44
Periodicals
BNP Paribas cutting 500 jobs at securities services arm in France, Reuters says »

BNP Paribas will cut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETR

Entergy

$111.35

-0.32 (-0.29%)

13:39
08/22/19
08/22
13:39
08/22/19
13:39
Syndicate
Breaking Syndicate news story on Entergy »

Entergy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

TELL

Tellurian

$9.04

0.75 (9.05%)

13:25
08/22/19
08/22
13:25
08/22/19
13:25
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
08/22/19
08/22
13:25
08/22/19
13:25
General news
Treasury's $7 B 30-year TIPS reopening was well received »

Treasury's $7 B…

13:21
08/22/19
08/22
13:21
08/22/19
13:21
General news
30-Yr TIPS Auction Bid/Cover data reported »

30-Yr TIPS Auction…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.